The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
Muted movement reflects consolidation phase as investors await earnings triggers
The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
One Health-based surveillance model to focus on bird sanctuaries and high-risk human populations
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
The national platform brought together healthcare professionals, patient advocates, and stakeholders
Former Wavemaker executive to lead media strategy and digital transformation agenda
Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%
Subscribe To Our Newsletter & Stay Updated
